Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Agenus Inc
(NQ:
AGEN
)
5.990
-0.060 (-0.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Agenus Inc
< Previous
1
2
3
4
Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm
September 18, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Agenus Inc. Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the AGEN Class Action Lawsuit
September 17, 2024
From
Robbins LLP
Via
Business Wire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN
September 16, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline
September 16, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm
September 14, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
September 13, 2024
From
Agenus Inc.
Via
Business Wire
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 12, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
AGENUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Agenus Inc. and Encourages Investors to Contact the Firm
September 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Agenus Inc.
September 10, 2024
From
Robbins LLP
Via
GlobeNewswire
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 09, 2024
From
The Schall Law Firm
Via
Business Wire
Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
September 09, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
AGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
September 09, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
September 09, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in September Investor Conferences
September 03, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Second Quarter 2024 Operational and Financial Results
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Appointment of Tom Harrison to Board of Directors
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
August 07, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
July 26, 2024
From
Agenus Inc.
Via
Business Wire
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
July 18, 2024
From
Schall Law Firm
Via
Business Wire
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
July 18, 2024
From
Agenus Inc.
Via
Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
June 28, 2024
From
Agenus Inc.
Via
Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
June 27, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
June 17, 2024
From
Agenus Inc.
Via
Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
June 13, 2024
From
Agenus
Via
Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
June 04, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2024
From
Agenus Inc.
Via
Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
May 23, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
May 23, 2024
From
Agenus Inc.
Via
Business Wire
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
May 16, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports First Quarter 2024 Results
May 07, 2024
From
Agenus Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.